Form 4: Day One Biopharmaceuticals Acquired by Servier

Director Habib J. Dable reports the disposition of equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Summary

• Habib J. Dable, a Director at Day One Biopharmaceuticals, filed a Form 4 reporting the disposition of all remaining stock options and restricted stock units (RSUs).
• The transactions occurred on April 23, 2026, coinciding with the closing of the merger between Day One Biopharmaceuticals and Servier Pharmaceuticals LLC.
• Under the merger agreement, all outstanding unvested equity awards were accelerated to full vesting immediately prior to the merger's effective time.
• The reporting person's equity holdings were canceled and converted into the right to receive cash consideration based on the $21.50 per share offer price, minus applicable exercise prices and withholding taxes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final equity settlement of a completed merger, which is a standard procedural event.

Positives

• Full acceleration of unvested stock options and RSUs provided immediate liquidity to the director upon the merger closing.
• The merger consideration of $21.50 per share represents a definitive exit event for shareholders and equity holders.

Negatives

• The company ceases to exist as an independent publicly traded entity following the merger completion.

Risks

• The company is no longer a standalone public entity, eliminating future growth potential for current shareholders.

Future Outlook

The company has been acquired by Servier Pharmaceuticals and will operate as a wholly owned subsidiary; therefore, no further independent forward-looking guidance is provided.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A transaction in the biopharmaceutical sector, reflecting ongoing consolidation trends where larger global players acquire specialized firms to bolster their oncology or rare disease pipelines.

Comparison to Industry Standards

• The acquisition price of $21.50 per share is consistent with standard premium-based exits for clinical-stage biopharmaceutical companies.
• The acceleration of unvested equity upon a change-in-control event is a standard provision in executive compensation agreements within the biotech industry.

Corporate Governance

Stakeholder Impact

• Shareholders receive cash consideration of $21.50 per share.
• Equity holders have had their holdings converted to cash.

Next Steps

• Delisting of Day One Biopharmaceuticals (DAWN) from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Merger, Acquisition, Servier Pharmaceuticals, Form 4, Insider Transaction